Array ( [1575987152] => Array ( [wordfence_hourly_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1575988773] => Array ( [wp_privacy_delete_old_export_files] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1575989281] => Array ( [wpm_update_stats] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1575991073] => Array ( [wp_session_garbage_collection] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1575994024] => Array ( [akismet_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1575997011] => Array ( [yoast_tracking] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1576027926] => Array ( [wp_update_themes] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) [wp_version_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) [wp_update_plugins] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1576048112] => Array ( [ai1wm_storage_cleanup] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1576054171] => Array ( [wp_scheduled_auto_draft_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1576059311] => Array ( [delete_expired_transients] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1576059352] => Array ( [wpseo-reindex-links] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1576066352] => Array ( [wordfence_daily_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1576071874] => Array ( [wp_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1576244998] => Array ( [wordfence_start_scheduled_scan] => Array ( [aa7fa86b6236edfd62c5aa4bb3cc7b04] => Array ( [schedule] => [args] => Array ( [0] => 1576244998 ) ) ) ) [1576504198] => Array ( [wordfence_start_scheduled_scan] => Array ( [7a4f79c8ff420a85198a4db07a2c669e] => Array ( [schedule] => [args] => Array ( [0] => 1576504198 ) ) ) ) [1576508400] => Array ( [wordfence_email_activity_report] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => [args] => Array ( ) ) ) ) [1580169600] => Array ( [publish_future_post] => Array ( [2d492587fa52e9c78f7043ddf937b0a1] => Array ( [schedule] => [args] => Array ( [0] => 18611 ) ) [dea3edad73162f380bc9dc44fa3407bf] => Array ( [schedule] => [args] => Array ( [0] => 19670 ) ) [2caa9c58a241c4f77a6856802c1b43fb] => Array ( [schedule] => [args] => Array ( [0] => 20734 ) ) [307b37ba29b8cd716eafa809661756e3] => Array ( [schedule] => [args] => Array ( [0] => 22852 ) ) [365be9eba8e62abb0c0d4bfe013a2687] => Array ( [schedule] => [args] => Array ( [0] => 23918 ) ) [0e942b20ffb9550322105263ad82126f] => Array ( [schedule] => [args] => Array ( [0] => 24977 ) ) [661c5eb39689fe2133ff7986ac6628fb] => Array ( [schedule] => [args] => Array ( [0] => 26036 ) ) [75562b264e355915e4dea97042a28f7e] => Array ( [schedule] => [args] => Array ( [0] => 27095 ) ) [11cf4e8a6f842b0115881551a29c47f6] => Array ( [schedule] => [args] => Array ( [0] => 28154 ) ) [55a38aaca11da398c854cb29a7d4f5e6] => Array ( [schedule] => [args] => Array ( [0] => 30272 ) ) [f8cbc904676c235c7057ec965c01c023] => Array ( [schedule] => [args] => Array ( [0] => 32390 ) ) ) ) [1583794819] => Array ( [publish_future_post] => Array ( [9d993985746691420cd7524448c48a23] => Array ( [schedule] => [args] => Array ( [0] => 448880 ) ) ) ) [1601157627] => Array ( [publish_future_post] => Array ( [aa3f9c41dd8e97586795881a0c603b8d] => Array ( [schedule] => [args] => Array ( [0] => 472787 ) ) ) ) )
Etiquetas: 2006, Acuerdo de precio en Enero-Diciembre 2006, Alglucosidasa Alfa, Condición de dispensación, Dexrazoxano, Dirección general de farmacia y productos sanitarios, Erlotinib, Euros, Galsulfasa, Grupo Terapéutico, Hormona Paratiroidea, Indicaciones, Información, Información contrastada, Madrid, medicamentos, Nombre comercial, Nuevos principios activos autorizados en 2006, Omalizumab, P.V.P, Palonosetron, Pegaptanib, Posaconazol, Presentación, Principio activo, Rotigotina, salud, Sanidad, Sildenafilo, Sorafenib, sunitinib, Tipranavir, Unidad de Utilidad Terapéutica de la Subdirección General de Calidad de Medicamentos.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x